Current Diabetes Reports

, Volume 12, Issue 1, pp 24–32 | Cite as

Diabetes-Induced Birth Defects: What Do We Know? What Can We Do?

Diabetes and Pregnancy (CJ Homko, Section Editor)

Abstract

Birth defects are the leading cause of infant mortality in the United States, which has one of the highest infant mortality rates in the developed world. Many of these birth defects can be attributed to pre-existing, or pregestational, diabetes in pregnancy, which significantly increases a mother’s risk of having a child with a major birth defect. Strict preconceptional and early pregnancy glucose control, supplementation with multivitamins and fatty acids, and lower glycemic dietary management have been shown to reduce the incidence of birth defects in experimental and epidemiologic studies. However, because more than half of pregnancies are unplanned, these methods are not generalizable across the population. Thus, better interventions are urgently needed. Based on what we know about the molecular pathophysiology of diabetic embryopathy, our laboratory and others are developing interventions against to key molecular targets in this multifactorial disease process.

Keywords

Antioxidant therapy Birth defects Fatty acid Folic acid Diabetic embryopathy Dietary supplementation Hyperglycemia Infant mortality Pregnancy Glucose control Molecular pathogenesis Preconception care Diabetes 

Notes

Disclosure

No potential conflict of interest relevant to this article was reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Save the Children. State of the World’s Mothers 2011. Champions for Children. Available at: http://www.savethechildren.org/atf/cf/%7B9def2ebe-10ae-432c-9bd0-df91d2eba74a%7D/SOWM2011_FULL_REPORT.PDF. Accessed 11-3-11.
  2. 2.
    Heron M, Tejada-Vera B. Deaths: leading causes for 2005. Natl Vital Stat Rep. 2009;58(8):1–97.PubMedGoogle Scholar
  3. 3.
    Birth Defects and Congenital Anomolies. Faststats. Available at: http://www.cdc.gov/nchs/fastats/bdefects.htm. Accessed 11-2-11.
  4. 4.
    World Health Organization. Birth Defects. Report by the Secretariat. Available on-line at: http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_10-en.pdf. Accessed 10-19-11
  5. 5.
    Fetita LS, Sobngwi E, Serradas P, et al. Consequences of fetal exposure to maternal diabetes in offspring. J Clin Endocrinol Metab. 2006;91:3718–24.PubMedCrossRefGoogle Scholar
  6. 6.
    Potenza MA, Nacci C, Gagliardi S, Montagnani M. Cardiovascular complications in diabetes: lessons from animal models. Curr Med Chem. 2011;18:1806–19.PubMedCrossRefGoogle Scholar
  7. 7.
    Eidem I, Stene LC, Henriksen T, et al. Congenital anomalies in newborns of women with type 1 diabetes: nationwide population-based study in Norway, 1999–2004. Acta Obstet Gynecol Scand. 2010;89:1403–11.PubMedCrossRefGoogle Scholar
  8. 8.
    Biggio Jr JR, Chapman V, Neely C, et al. Fetal anomalies in obese women: the contribution of diabetes. Obstet Gynecol. 2010;115:290–6.PubMedCrossRefGoogle Scholar
  9. 9.
    Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. Am J Obstet Gynecol. 2008;199:237.e1–9.CrossRefGoogle Scholar
  10. 10.
    Reece EA, Homko CJ, Wu YK. Multifactorial basis of the syndrome of diabetic embryopathy. Teratology. 1996;54:171–82.PubMedCrossRefGoogle Scholar
  11. 11.
    Reece EA, Pinter E, Homko C, et al. The yolk sac theory: closing the circle on why diabetes-associated malformations occur. J Soc Gynecol Investig. 1994;1:3–13.PubMedGoogle Scholar
  12. 12.
    Mironiuk M, Kietlińska Z, Jezierska-Kasprzyk K, Piekosz-Orzechowska B. A class of diabetes in mother, glycemic control in early pregnancy and occurrence of congenital malformations in newborn infants. Clin Exp Obstet Gynecol. 1997;24:193–7.PubMedGoogle Scholar
  13. 13.
    Reece EA, Gabrielli S, Abdalla M. The prevention of diabetes-associated birth defects. Semin Perinatol. 1988;12:292–301.PubMedGoogle Scholar
  14. 14.
    Hone J, Jovanovic L. Approach to the patient with diabetes during pregnancy. J Clin Endocrinol Metab. 2010;95:3578–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Homko CJ, Khandelwal M. Glucose monitoring and insulin therapy during pregnancy. Obstet Gynecol Clin North Am. 1996;23:47–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Reece EA, Homko CJ. Diabetes mellitus in pregnancy. What are the best treatment options? Drug Saf. 1998;18:209–20.PubMedCrossRefGoogle Scholar
  17. 17.
    Kitzmiller JL, Gavin LA, Gin GD, et al. Preconception care of diabetes. Glycemic control prevents congenital anomalies. JAMA. 1991;265:731–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Fuhrmann K, Reiher H, Semmler K, Glöckner E. The effect of intensified conventional insulin therapy before and during pregnancy on the malformation rate in offspring of diabetic mothers. Exp Clin Endocrinol. 1984;83:173–7.PubMedCrossRefGoogle Scholar
  19. 19.
    Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006;38:90–6.PubMedCrossRefGoogle Scholar
  20. 20.
    HAPO Study Cooperative Research Group, Metzger BE, Lowe LP, et al. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991–2002.PubMedCrossRefGoogle Scholar
  21. 21.
    Dalewitz J, Khan N, Hershey CO. Barriers to control of blood glucose in diabetes mellitus. Am J Med Qual. 2000;15:16–25.PubMedCrossRefGoogle Scholar
  22. 22.
    Hay LC, Wilmshurst EG, Fulcher G. Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther. 2003;5:19–26.PubMedCrossRefGoogle Scholar
  23. 23.
    Vaddiraju S, Burgess DJ, Tomazos I, et al. Technologies for continuous glucose monitoring: current problems and future promises. J Diabetes Sci Technol. 2010;4:1540–62.PubMedGoogle Scholar
  24. 24.
    Wilson RD, Johnson JA, Wyatt P, et al. Pre-conceptional vitamin/folic acid supplementation 2007: the use of folic acid in combination with a multivitamin supplement for the prevention of neural tube defects and other congenital anomalies. J Obstet Gynaecol Can. 2007;29:1003–26.PubMedGoogle Scholar
  25. 25.
    Bánhidy F, Dakhlaoui A, Puhó EH, Czeizel AA. Is there a reduction of congenital abnormalities in the offspring of diabetic pregnant women after folic acid supplementation? A population-based case–control study. Congenit Anom (Kyoto). 2011;51:80–6.CrossRefGoogle Scholar
  26. 26.
    Correa A, Botto L, Liu Y, Mulinare J, Erickson JD. Do multivitamin supplements attenuate the risk for diabetes-associated birth defects? Pediatrics. 2003;111:1146–51.PubMedGoogle Scholar
  27. 27.
    Wallach JB, Rey MJ. A socioeconomic analysis of obesity and diabetes in New York City. Prev Chronic Dis. 2009;6:A108.PubMedGoogle Scholar
  28. 28.
    Waller K. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med. 2007;161:745–50.PubMedCrossRefGoogle Scholar
  29. 29.
    Carmichael SL, Yang W, Feldkamp ML, et al. Reduced risks of neural tube defects and orofacial clefts with higher diet quality. Arch Pediatr Adolesc Med. 2011; Oct 3. [Epub ahead of print]Google Scholar
  30. 30.
    Stotland NE, Gilbert P, Bogetz A, et al. Preventing excessive weight gain in pregnancy: how do prenatal care providers approach counseling? J Womens Health (Larchmt). 2010;19:807–14.CrossRefGoogle Scholar
  31. 31.
    Jay M, Gillespie C, Ark T, et al. Do internists, pediatricians, and psychiatrists feel competent in obesity care? Using a needs assessment to drive curriculum design. J Gen Intern Med. 2008;23:1066–70.PubMedCrossRefGoogle Scholar
  32. 32.
    Chang MW, Nitzke S, Guilford E, et al. Motivators and barriers to healthful eating and physical activity among low-income overweight and obese mothers. J Am Diet Assoc. 2008;108:1023–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Reece EA, Homko CJ. Prepregnancy care and the prevention of fetal malformations in the pregnancy complicated by diabetes. Clin Obstet Gynecol. 2007;50:990–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Piomelli D. Arachidonic acid in cell signalling. Austin: Chapmam and Hall; 1996.Google Scholar
  35. 35.
    Jawerbaum A, Gonzalez E. The role of alterations in arachidonic acid metabolism and nitric oxide homeostasis in rat models of diabetes during early pregnancy. Curr Pharm Des. 2005;11:1327–42.PubMedCrossRefGoogle Scholar
  36. 36.
    Wiznitzer A, Furman B, Mazor M, Reece EA. The role of prostanoids in the development of diabetic embryopathy. Semin Reprod Endocrinol. 1999;17:175–81.PubMedCrossRefGoogle Scholar
  37. 37.
    Chang HY, Locker J, Lu R, Schuster VL. Failure of postnatal ductus arteriosus closure in prostaglandin transporter-deficient mice. Circulation. 2010;121:529–36.PubMedCrossRefGoogle Scholar
  38. 38.
    Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–20.PubMedCrossRefGoogle Scholar
  39. 39.
    Kukuljan M, Vergara L, Stojilkovic SS. Modulation of the kinetics of inositol 1,4,5-trisphosphate-induced [Ca2+]i oscillations by calcium entry in pituitary gonadotrophs. Biophys J. 1997;72:698–707.PubMedCrossRefGoogle Scholar
  40. 40.
    Larner J. D-chiro-inositol—its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res. 2002;3:47–60.PubMedCrossRefGoogle Scholar
  41. 41.
    Gerasimenko JV, Flowerdew SE, Voronina SG, et al. Bile acids induce Ca2+ release from both the endoplasmic reticulum and acidic intracellular calcium stores through activation of inositol trisphosphate receptors and ryanodine receptors. J Biol Chem. 2006;281:40154–63.PubMedCrossRefGoogle Scholar
  42. 42.
    Rapiejko PJ, Northup JK, Evans T, et al. G-proteins of fat-cells. Role in hormonal regulation of intracellular inositol 1,4,5-trisphosphate. Biochem J. 1986;240:35–40.PubMedGoogle Scholar
  43. 43.
    Shen X, Xiao H, Ranallo R, et al. Modulation of ATP-dependent chromatin-remodeling complexes by inositol polyphosphates. Science. 2003;299:112–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Steger DJ, Haswell ES, Miller AL, et al. Regulation of chromatin remodelling by inositol polyphosphates. Science. 2003;299:114–6.PubMedCrossRefGoogle Scholar
  45. 45.
    Pinter E, Reece EA, Leranth CZ, Garcia-Segura M, Hobbins JC, Mahoney MJ, et al. Arachidonic acid prevents hyperglycemia-associated yolk sac damage and embryopathy. Am J Obstet Gynecol. 1986;155:691–702.PubMedGoogle Scholar
  46. 46.
    Wiznitzer A, Ayalon N, Hershkovitz R, et al. Am J Obstet Gynecol. 1999;180:188–93.PubMedCrossRefGoogle Scholar
  47. 47.
    James AM, Murphy MP. How mitochondrial damage affects cell function. J Biomed Sci. 2002;9:475–87.PubMedCrossRefGoogle Scholar
  48. 48.
    Nishikawa T, Edelstein D, Du XL, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787–90.PubMedCrossRefGoogle Scholar
  49. 49.
    Hagay ZJ, Weiss Y, Zusman I, et al. Prevention of diabetes-associated embryopathy by overexpression of the free radical scavenger copper zinc superoxide dismutase in transgenic mouse embryos. AJOG. 1995;173:1036–41.CrossRefGoogle Scholar
  50. 50.
    Mao LM, Liu XY, Zhang GC, et al. Phosphorylation of group I metabotropic glutamate receptors (mGluR1/5) in vitro and in vivo. Neuropharmacology. 2008;55:403–8.PubMedCrossRefGoogle Scholar
  51. 51.
    Steinberg SF. Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J. 2004;384:449–59.PubMedCrossRefGoogle Scholar
  52. 52.
    Dempsey EC, Newton AC, Mochly-Rosen D, et al. Protein kinase C isozymes and the regulation of diverse cell responses. Am J Physiol Lung Cell Mol Physiol. 2000;279:L429–38.PubMedGoogle Scholar
  53. 53.
    Pearson G, Robinson F, Beers Gibson T, et al. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev. 2001;22:153–83.PubMedCrossRefGoogle Scholar
  54. 54.
    Alnemri ES, Livingston DJ, Nicholson DW, et al. Human ICE/CED-3 protease nomenclature. Cell. 1996;87:171.PubMedCrossRefGoogle Scholar
  55. 55.
    Fuentes-Prior P, Salvesen GS. The protein structures that shape caspase activity, specificity, activation and inhibition. Biochem J. 2004;384:201–32.PubMedCrossRefGoogle Scholar
  56. 56.
    Koenen TB, Stienstra R, van Tits LJ, et al. Hyperglycemia activates caspase-1 and TXNIP-mediated IL-1beta transcription in human adipose tissue. Diabetes. 2011;60:517–24.PubMedCrossRefGoogle Scholar
  57. 57.
    Kuan CY, Yang DD, Samanta Roy DR, et al. The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. Neuron. 1999;22:667–76.PubMedCrossRefGoogle Scholar
  58. 58.
    • Zhao Z, Yang P, Eckert RL, Reece EA. Caspase-8: a key role in the pathogenesis of diabetic embryopathy. Birth Defects Res B DevReprodToxicol. 2009;86:72–7. This study has had an important impact because it was the first to confirm the role of caspase-8 in diabetic embryopathy.CrossRefGoogle Scholar
  59. 59.
    Yang P, Zhao Z, Reece EA. Involvement of c-Jun N-terminal kinases activation in diabetic embryopathy. Biochem Biophys Res Commun. 2007;357:749–54.PubMedCrossRefGoogle Scholar
  60. 60.
    • Zhao Z, Yang P, Eckert RL, Reece EA. Caspase-8: a key role in the pathogenesis of diabetic embryopathy. Birth Defects Res B Dev Reprod Toxicol. 2009;86:72–7. This article has had a significant impact because it was the first to confirm the role of caspase-8 in the pathophysiology of diabetic embryopathy.PubMedCrossRefGoogle Scholar
  61. 61.
    Reece EA, Wu YK. Prevention of diabetic embryopathy in offspring of diabetic rats with use of a cocktail of deficient substrates and an antioxidant. Am J Obstet Gynecol. 1997;176:790–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Kappen C, Kruger C, MacGowan J, Salbaum JM. Maternal diet modulates the risk for neural tube defects in a mouse model of diabetic pregnancy. Reprod Toxicol. 2011;31:41–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Pinter E, Reece EA, Leranth CZ, et al. Yolk sac failure in embryopathy due to hyperglycemia: ultrastructural analysis of yolk sac differentiation associated with embryopathy in rat conceptuses under hyperglycemic conditions. Teratology. 1986;33:73–84.PubMedCrossRefGoogle Scholar
  64. 64.
    Reece EA, Wu YK, Wiznitzer A, et al. Dietary polyunsaturated fatty acid prevents malformations in offspring of diabetic rats. Am J Obstet Gynecol. 1996;175:818–23.PubMedCrossRefGoogle Scholar
  65. 65.
    Reece EA, Wu YK, Zhao Z, Dhanasekaran D. Dietary vitamin and lipid therapy rescues aberrant signaling and apoptosis and prevents hyperglycemia-induced diabetic embryopathy in rats. Am J Obstet Gynecol. 2006;194:580–5.PubMedCrossRefGoogle Scholar
  66. 66.
    Khandelwal M, Reece EA, Wu YK, Borenstein M. Dietary myo-inositol therapy in hyperglycemia-induced embryopathy. Teratology. 1998;57:79–84.PubMedCrossRefGoogle Scholar
  67. 67.
    Wentzel P, Thunberg L, Eriksson UJ. Teratogenic effect of diabetic serum is prevented by supplementation of superoxide dismutase and N-acetylcysteine in rat embryo culture. Diabetologia. 1997;40:7–14.PubMedCrossRefGoogle Scholar
  68. 68.
    • Li X, Weng H, Reece EA, Yang P. SOD1 overexpression in vivo blocks hyperglycemia-induced specific PKC isoforms: substrate activation and consequent lipid peroxidation in diabetic embryopathy. Am J Obstet Gynecol. 2011 Mar 5;[Epub ahead of print]. This article has had a significant impact because it not only confirmed the role of the PKC pathway in diabetic embryopathy, but it also demonstrated that this pre-apoptotic cascade could be blocked and is a modifiable drug target.Google Scholar
  69. 69.
    •• Cao Y, Zhao Z, Eckert RL, Reece EA. Protein kinase Cβ2 inhibition reduces hyperglycemia-induced neural tube defects through suppression of a caspase 8-triggered apoptotic pathway. Am J Obstet Gynecol. 2011;204:226.e1–5. This paper demonstrated that not only can we reduce the risk of hyperglycemia-induced NTDs by inhibition of a specific PKC isoform, PKCβ2, but also that the mode of action is via suppression of the cellular apoptotic pathway. It further confirms that our approach to preventing diabetic embryopathies is justified and that there are multiple points in the pathophysiology of this disease that are potential therapeutic targets.CrossRefGoogle Scholar
  70. 70.
    Rothenberg SP. Increasing the dietary intake of folate: pros and cons. Semin Hematol. 1999;36:65–74.PubMedGoogle Scholar
  71. 71.
    Tessema J, Jefferds ME, Cogswell M, Carlton E. Motivators and barriers to prenatal supplement use among minority women in the United States. J Am Diet Assoc. 2009;109:102–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Reece EA. New developments in the prevention of diabetes-induced neural tube defects. Prenat Neonatal Med. 1996;1:97–9.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.University of Maryland School of MedicineBaltimoreUSA

Personalised recommendations